Wat is de prijs voor Bellicum Pharmaceuticals, Inc. (BLCM)

Het prijs van Bellicum Pharmaceuticals, Inc. (BLCM) is $0.07475

Wat is de marktkapitalisatie voor Bellicum Pharmaceuticals, Inc. (BLCM)

Marktkapitalisatie voorBellicum Pharmaceuticals, Inc. (BLCM) is $755.60K

Bellicum Pharmaceuticals, Inc. (BLCM) Dividendrendement

Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.

Jaar	Dividendrendement	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Dividendrendement

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Dividendrendement	Land
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.65%	BE

Bedrijf

Dividendrendement

Land